Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancerSibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
JNCI Cancer Spectrum|January 25, 2021
Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association DataSangkyu Lee, Joseph O Deasy, Jung Hun Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Analytical Chemistry|April 13, 2022
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGSCeline Callens, Francois-Clement Bidard, Anaïs Curto-Taribo, et al.
Nature Medicine|May 6, 2016
Facilitating a culture of responsible and effective sharing of cancer genome dataLillian L Siu, Mark Lawler, David Haussler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerThomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Cancer|April 22, 2021
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvementsAntonio Di Meglio, Arnauld S Gbenou, Elise Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Nature Communications|October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancerSibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
JNCI Cancer Spectrum|January 25, 2021
Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association DataSangkyu Lee, Joseph O Deasy, Jung Hun Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Analytical Chemistry|April 13, 2022
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGSCeline Callens, Francois-Clement Bidard, Anaïs Curto-Taribo, et al.
Nature Medicine|May 6, 2016
Facilitating a culture of responsible and effective sharing of cancer genome dataLillian L Siu, Mark Lawler, David Haussler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerThomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Cancer|April 22, 2021
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvementsAntonio Di Meglio, Arnauld S Gbenou, Elise Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Nature Communications|October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Pageof 15